Zhi Tong Cai Jing·2025-08-29 10:25Core Viewpoint - Fosun Pharma has signed a licensing agreement with Aikono for the exclusive rights to research, develop, produce, register, and commercialize the AC-201 molecule and any drugs containing it in China and Hong Kong, Macau, focusing on autoimmune diseases [1] Group 1 - The licensing agreement involves a payment of up to RMB 156 million, which includes an upfront payment and milestone payments [1] - AC-201 is an oral small molecule JAK inhibitor developed by Aikono, primarily targeting autoimmune diseases [1] - The first indication for AC-201, moderate to severe plaque psoriasis, has completed Phase II clinical trials in China, showing good safety and tolerability without serious adverse events [1] Group 2 - The Phase II clinical trial data for AC-201 is positive, with all three dosage groups meeting primary and key secondary endpoints after 12 weeks of treatment [1] - This collaboration aims to leverage the company's strengths in drug clinical development, registration, production, and commercialization, enhancing its product pipeline in the autoimmune field and improving market positioning [1]